



Dr. Marco Siano

contact

titel	Dr. med.
first name	Marco
last name	Siano
street	Rorschacherstrasse 95
city	9007 St. Gallen
country	Switzerland
phone number	+41 71 494 11 11
fax	+41 71 494 6325
e-mail	marco.siano@kssg.ch

research profile

academic status	Oberarzt/Oberärztin
department	I
faculty	Onkologie/Hämatologie
affiliations	FHM, VSAO, SGMO, ESMO, ASCO

publications

title

**journal
paper/
review**

Zürrer-Härdi U, Siano M, Broglie Däppen M. Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom. Schweiz. Krebs Bulletin 2015; 1:98-101.

Litschel R, Siano M, Tasman A J, Cogliatti S B. Nasolacrimal duct obstruction caused by lymphoproliferative infiltration in the course of chronic lymphocytic leukemia. Allergy Rhinol (Providence) 2015; 6:191-4.

Zürrer-Härdi U, Siano M. Antiemese und Tumormedikation. info@onkologie.ch 2015; 1:20-26.

AC V, Siano M, Broglie Däppen M, Töpfer M, Stöckli S. Das Adenoidzystische-Karzinom. info@onkologie.ch 2015; 1:10-12.

Siano M. Schilddrüsenkarzinom – News-ASCO und Integration in den klinischen Alltag. Leading Opinions Hämatologie & Onkologie 2015; 4:..

Feilchenfeldt J, Varga Z, Siano M, Grabsch H I, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer 2015; 113:716-21.

Böhler N, Siano M, Anliker M D. Phototoxische Medikamente: Wichtigkeit der Patienteninstruktion. Swiss Medical Forum 2014; 14:132-134.

Siano M. CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. memo 2013; 6:75-82.

publications

title

journal paper/ review

Siano M. Medulläres Schilddrüsenkarzinom – Eine eigene Entität.
info@onkologie 2013 2013; 3:37-39.

Bossi P, Siano M. Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy. JCO Journal of Clinical Oncology 2013; 31:.

Hochstrasser A, Hundsberger T, Siano M. Secondary spinal anaplastic ependymoma ten years after treatment of Hodgkin's disease. Schweiz. Krebs Bulletin 2013; 2:175-178.

Siano M. Die Therapie beim NSCLC in kurativer Absicht: Aktuelle Modalitäten in allen Krankheitsstadien: eine Übersicht. Schweizerische Zeitschrift für Onkologie 2012;17-22.

Siano M. Systemic therapy of neuroendocrine tumors of the lung: Review. Lung Cancer Management 2012; 1:1-8.

Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M, Swiss Group for Clinical Cancer Research . Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2012; 14:34-9.

Uster A, Rühlin M, Rüfenacht U, Pless M, Siano M, Imoberdorf R, Ballmer p. Individuelle Ernährungsberatung bewirkt eine signifikante Steigerung der Energie- und Eiweisszufuhr bei unterernährten, ambulanten Krebspatienten: Eine kontrollierte, randomisierte Studie. Ernährung 2012;.

publications

title

journal paper/ review

Siano M, Lerch E, Negretti L, Zucca E, Rodriguez-Abreu D, Oberson M, Leoncini L, Mora O, Sessa C, Gallino A, Ghielmini M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2008; 14:7935-9.

Siano M. Wirksamkeit von Alemtuzumab und Gemcitabine in einer Patientin mit enteropathischem T-Zell Lymphom: Der seltene Fall. *Schweizer Krebsbulletin* 2007; 27:.

Siano M. Vaginal sacrospinous ligament fixation - a minimal invasive procedure?. *Dissertation* 2005;.

conference paper/ poster

Siano M (2015). Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival. In *J Clin Oncol* 33, 2015 (suppl; abstract e17046). (pp. 1): JCO.

Siano M (2015). Thyroid cancers: which molecular markers are relevant?. In *Oncol Res Treat* 2015;38(suppl 5):42 (abstract V154) (pp. 42): Karger.

Cau M, Alfieri S, & Siano M (2015). Site of metastatic disease influences adenoid cystic cancer (ACC) patients' outcome. In *Ann of Oncol* 2015 26 (suppl 6):vi67-vi72. (pp. 67): oxfordpress.

Siano M (2015). Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC). In *Eur J Cancer* 2015;51(suppl 3);S560. abstract 2807 (pp. 560): Elsevier.

publications

title

conference paper/ poster

Siano M (2015). Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC). In Eur J Cancer 2015;51(suppl 3);S576. abstract 2861. (pp. 576): Elsevier.

Siano M, Resteghini c, Licitra L, & Bossi P (2015). Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective analysis. In Eur J Cancer 2015;51(suppl 3); S578. abstract 2865. (pp. 578): Elsevier.

Feilchenfeldt J, Varga Z, Schuknecht B, Siano M, & Hofer S (2014). Gastric cancer and CNS involvement registry. In (pp. S10).

presentation

Siano M (2015). Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB). Presented at DGHO 2015, Basel.

Siano M (2015). Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre. Presented at DGHO 2015.

projects

title	status
A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib	automatically closed
Cytochrom p450 3A4 and 1A2 phenotyping for the individualization of treatment with sunitinib or erlotinib in cancer patients	automatically closed
ETOP 2-11 (BELIEF) An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations	ongoing - follow up
A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy	automatically closed



projects

title	status
Phase II study to investigate the efficacy of panitumumab in platinum-resistant advanced head and neck squamous cancer	automatically closed
An open-label, randomized, parallel group study of patients treated with Paclitaxel with standard dosing versus pharmacokinetic guided dose adjustment in patients with advanced NSCLC	completed

projects

title	status
Bevacizumab, pemetrexed and cisplatin, or erlotinib and bevacizumab for advanced non-squamous NSCLC stratified by EGFR mutation status. A multicenter phase II trial including biopsy at progression (BIO-PRO trial)	automatically closed
Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial	automatically closed
Carboplatin and Paclitaxel plus ASA404 as first line chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): A phase II trial	automatically closed